Related Experiment Videos
Inhibition of tumor angiogenesis
E P Sipos1, R J Tamargo, J D Weingart
1Department of Neurological Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Abstract:
The exponential growth of solid tumors depends upon induction of new vessel growth, a process mediated by diffusable angiogenic factors produced by tumor cells. By inhibiting angiogenesis, it is now possible to modulate tumor growth and metastasis in laboratory animals. The first described inhibitor of angiogenesis was a protein derived from cartilage. Other important classes of antiangiogenic agents include angiostatic steroids combined with heparin or heparin derivatives, and the synthetic derivatives of fumigallin. As the mechanisms of action of these and other angiostatic agents are being elucidated, it is becoming apparent that many modulators of collagen metabolism inhibit angiogenesis and may offer clinically useful anticancer treatments. Minocycline and other tetracycline derivatives with anticollagenase properties have been shown to be potent inhibitors of angiogenesis. These agents, when administered with other standard cancer therapies, help prolong survival in laboratory animals with solid tumors. Further studies of these biologic response modifiers of tumor progression are under way in the hope that they will offer effective new treatments for cancer in humans.
Insights
Inhibiting tumor angiogenesis, the growth of new blood vessels, can slow cancer progression. Certain tetracycline derivatives, like minocycline, show promise as antiangiogenic agents for cancer treatment.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Solid tumor growth relies on angiogenesis, a process driven by tumor-secreted factors.
- Inhibiting angiogenesis is a validated strategy to control tumor growth and metastasis in preclinical models.
- Early antiangiogenic agents included cartilage-derived proteins and angiostatic steroids.
Purpose of the Study:
- To explore novel antiangiogenic agents for cancer therapy.
- To investigate the role of collagen metabolism modulators in inhibiting angiogenesis.
- To evaluate tetracycline derivatives as potential anticancer treatments.
Main Methods:
- Review of existing literature on angiogenesis inhibitors.
- Analysis of the mechanism of action of various antiangiogenic agents.
- Preclinical studies assessing the efficacy of tetracycline derivatives in combination with standard therapies.
Main Results:
- Modulators of collagen metabolism, including tetracyclines, demonstrate potent inhibition of angiogenesis.
- Minocycline and related compounds exhibit significant antiangiogenic properties.
- Administration of these agents prolonged survival in animal models of solid tumors.
Conclusions:
- Tetracycline derivatives with anticollagenase activity are effective inhibitors of angiogenesis.
- These compounds represent a promising class of biologic response modifiers for cancer treatment.
- Further research is warranted to translate these findings into human cancer therapies.